33.179 USD
+0.25 (+0.76%)
Overall GMAB gets a fundamental rating of 7 out of 10. We evaluated GMAB against 525 industry peers in the Biotechnology industry. GMAB gets an excellent profitability rating and is at the same time showing great financial health properties. GMAB is not priced too expensively while it is growing strongly. Keep and eye on this one! These ratings would make GMAB suitable for growth and quality investing!
1. Profitability
1.1 Basic Checks
- In the past year GMAB was profitable.
- In the past year GMAB had a positive cash flow from operations.
- GMAB had positive earnings in each of the past 5 years.
- GMAB had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
- The Return On Assets of GMAB (21.10%) is better than 97.33% of its industry peers.
- GMAB has a Return On Equity of 25.76%. This is amongst the best in the industry. GMAB outperforms 97.14% of its industry peers.
- With an excellent Return On Invested Capital value of 17.11%, GMAB belongs to the best of the industry, outperforming 96.76% of the companies in the same industry.
- The Average Return On Invested Capital over the past 3 years for GMAB is below the industry average of 18.07%.
- The 3 year average ROIC (15.20%) for GMAB is below the current ROIC(17.11%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 21.1% | ||
| ROE | 25.76% | ||
| ROIC | 17.11% |
ROA(3y)15.92%
ROA(5y)16.24%
ROE(3y)18.48%
ROE(5y)18.5%
ROIC(3y)15.2%
ROIC(5y)16.1%
1.3 Margins
- GMAB's Profit Margin of 41.35% is amongst the best of the industry. GMAB outperforms 97.33% of its industry peers.
- GMAB's Profit Margin has declined in the last couple of years.
- The Operating Margin of GMAB (36.85%) is better than 97.90% of its industry peers.
- In the last couple of years the Operating Margin of GMAB has declined.
- GMAB has a Gross Margin of 94.27%. This is amongst the best in the industry. GMAB outperforms 94.86% of its industry peers.
- GMAB's Gross Margin has declined in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 36.85% | ||
| PM (TTM) | 41.35% | ||
| GM | 94.27% |
OM growth 3Y-2.13%
OM growth 5Y-7.73%
PM growth 3Y1.23%
PM growth 5Y-2.03%
GM growth 3Y-1.55%
GM growth 5YN/A
2. Health
2.1 Basic Checks
- GMAB has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
- GMAB has less shares outstanding than it did 1 year ago.
- The number of shares outstanding for GMAB has been reduced compared to 5 years ago.
- GMAB has a worse debt/assets ratio than last year.
2.2 Solvency
- GMAB has an Altman-Z score of 12.16. This indicates that GMAB is financially healthy and has little risk of bankruptcy at the moment.
- GMAB has a Altman-Z score of 12.16. This is amongst the best in the industry. GMAB outperforms 84.38% of its industry peers.
- GMAB has a debt to FCF ratio of 0.12. This is a very positive value and a sign of high solvency as it would only need 0.12 years to pay back of all of its debts.
- Looking at the Debt to FCF ratio, with a value of 0.12, GMAB belongs to the top of the industry, outperforming 95.81% of the companies in the same industry.
- A Debt/Equity ratio of 0.02 indicates that GMAB is not too dependend on debt financing.
- The Debt to Equity ratio of GMAB (0.02) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.02 | ||
| Debt/FCF | 0.12 | ||
| Altman-Z | 12.16 |
ROIC/WACC2.34
WACC7.32%
2.3 Liquidity
- A Current Ratio of 6.03 indicates that GMAB has no problem at all paying its short term obligations.
- The Current ratio of GMAB (6.03) is better than 62.86% of its industry peers.
- GMAB has a Quick Ratio of 6.01. This indicates that GMAB is financially healthy and has no problem in meeting its short term obligations.
- GMAB's Quick ratio of 6.01 is fine compared to the rest of the industry. GMAB outperforms 63.81% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 6.03 | ||
| Quick Ratio | 6.01 |
3. Growth
3.1 Past
- The Earnings Per Share has grown by an impressive 125.90% over the past year.
- GMAB shows a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 28.38% yearly.
- Looking at the last year, GMAB shows a very strong growth in Revenue. The Revenue has grown by 24.66%.
- Measured over the past years, GMAB shows a very strong growth in Revenue. The Revenue has been growing by 31.16% on average per year.
EPS 1Y (TTM)125.9%
EPS 3Y34.24%
EPS 5Y28.38%
EPS Q2Q%121.44%
Revenue 1Y (TTM)24.66%
Revenue growth 3Y32.63%
Revenue growth 5Y31.16%
Sales Q2Q%-81.55%
3.2 Future
- GMAB is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 9.30% yearly.
- GMAB is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 13.38% yearly.
EPS Next Y6.42%
EPS Next 2Y-1.8%
EPS Next 3Y6.27%
EPS Next 5Y9.3%
Revenue Next Year22.77%
Revenue Next 2Y19.6%
Revenue Next 3Y17.39%
Revenue Next 5Y13.38%
3.3 Evolution
- When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
- Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
- GMAB is valuated correctly with a Price/Earnings ratio of 14.06.
- Compared to the rest of the industry, the Price/Earnings ratio of GMAB indicates a rather cheap valuation: GMAB is cheaper than 97.14% of the companies listed in the same industry.
- GMAB is valuated cheaply when we compare the Price/Earnings ratio to 28.60, which is the current average of the S&P500 Index.
- With a Price/Forward Earnings ratio of 19.49, GMAB is valued on the expensive side.
- Based on the Price/Forward Earnings ratio, GMAB is valued cheaper than 93.90% of the companies in the same industry.
- GMAB is valuated rather cheaply when we compare the Price/Forward Earnings ratio to 25.83, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 14.06 | ||
| Fwd PE | 19.49 |
4.2 Price Multiples
- 96.95% of the companies in the same industry are more expensive than GMAB, based on the Enterprise Value to EBITDA ratio.
- 96.19% of the companies in the same industry are more expensive than GMAB, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 16.98 | ||
| EV/EBITDA | 11.08 |
4.3 Compensation for Growth
- The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
- The decent profitability rating of GMAB may justify a higher PE ratio.
PEG (NY)2.19
PEG (5Y)0.5
EPS Next 2Y-1.8%
EPS Next 3Y6.27%
5. Dividend
5.1 Amount
- GMAB does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
GENMAB A/S -SP ADR / GMAB FAQ
What is the ChartMill fundamental rating of GENMAB A/S -SP ADR (GMAB) stock?
ChartMill assigns a fundamental rating of 7 / 10 to GMAB.
What is the valuation status for GMAB stock?
ChartMill assigns a valuation rating of 6 / 10 to GENMAB A/S -SP ADR (GMAB). This can be considered as Fairly Valued.
Can you provide the profitability details for GENMAB A/S -SP ADR?
GENMAB A/S -SP ADR (GMAB) has a profitability rating of 7 / 10.
Can you provide the PE and PB ratios for GMAB stock?
The Price/Earnings (PE) ratio for GENMAB A/S -SP ADR (GMAB) is 14.06 and the Price/Book (PB) ratio is 3.55.
Can you provide the financial health for GMAB stock?
The financial health rating of GENMAB A/S -SP ADR (GMAB) is 8 / 10.